Skip to main content
. Author manuscript; available in PMC: 2020 Aug 7.
Published in final edited form as: Am J Perinatol. 2019 Feb 7;37(3):281–290. doi: 10.1055/s-0039-1678535

Table 4.

Genotype frequencies and odds ratios for cases and controls,a by sex, for stratified neurodevelopmental outcomesb

Gene RS Allele Males Females p-Value for heterogeneity
Cases Controls OR (95% Cl) p-Value Cases Controls OR (95% Cl) p-Value
m/M MM Mm mm MM Mm mm MM Mm mm MM Mm mm
Psychomotor delay
IL1β 1143623 G/C 57.9 36.8 5.3 70.7 25.9 3.4 2.1 (0.8–5.4) 0.14 70.6 20.6 8.8 51.4 42.9 5.7 0.6 (0.2–1.8) 0.32 0.04
IL6 2069840 G/C 59.3 33.9 6.8 49.1 36.8 14.0 0.5 (0.2–1.1) 0.10 46.9 43.8 9.4 66.7 27.3 6.1 2.0 (0.7–5.5) 0.20 0.05
IL10 1800896 C/T 27.3 60.0 12.7 44.6 42.9 12.5 5.3 (1.6–17.6) 0.007 51.5 24.2 24.2 35.3 41.2 23.5 0.6 (0.2–1.4) 0.22 0.005
AQP4 9951307 G/A 27.6 58.6 13.8 36.2 46.6 17.2 1.0 (0.5–2.1) 0.91 21.9 62.5 15.6 43.8 50.0 6.3 NA 0.07 0.03
Mental delay
IL6 1880243 A/C 65.3 25.0 9.7 65.8 31.5 2.7 1.0 (0.5–1.9) 0.93 58.8 35.3 5.9 78.4 21.6 0 4.1 (0.9–18.7) 0.07 0.02
IL6 1800796 C/G 76.3 17.1 6.6 74.7 20.0 5.3 1.2 (0.6–2.4) 0.62 77.8 22.2 0 67.7 23.5 8.8 0.3 (0.1–0.9) 0.04 0.02
IL6 2069840 G/C 58.1 31.1 10.8 53.5 35.2 11.3 0.7 (0.4–1.5) 0.37 42.4 42.4 15.2 66.7 27.8 5.6 3.6 (1.1–12.1) 0.04 0.02
IL6R 7549338 C/G 32.9 51.4 15.7 46.5 40.8 12.7 1.9 (1.0–3.7) 0.05 41.9 41.9 16.1 29.4 47.1 23.5 0.6 (0.2–1.9) 0.37 0.04
IL6R 7549250 C/T 22.9 57.1 20.0 48.4 34.4 17.2 1.7 (0.9–3.2) 0.08 30.6 58.3 11.1 25.7 51.4 22.9 0.4 (0.2–1.2) 0.09 0.01
F7 6046 A/G 74.2 25.8 0 81.8 16.7 1.5 2.0 (0.7–5.4) 0.20 96.4 0 3.6 69.0 27.6 3.5 0.1 (0.0–1.5) 0.10 0.03
TLR1 5743551 T/C 45.7 35.7 18.6 39.2 32.4 28.4 0.6 (0.3–1.2) 0.18 29.7 48.6 21.6 54.3 28.6 17.1 2.6 (0.9–7.3) 0.08 0.02
Death/cerebral palsy
IL1β 16944 A/G 34.9 34.9 30.2 37.8 50.0 12.2 1.9 (0.9–4.1) 0.12 29.2 45.8 25.0 34.0 38.3 27.7 0.5 (0.2–1.2) 0.13 0.01
IL1β 4848306 A/G 65.1 23.3 11.6 36.1 50.6 13.3 0.5 (0.2–1.3) 0.15 52.0 36.0 12.0 54.2 37.5 8.3 1.7 (0.7–3.9) 0.23 0.04
IL6 2069840 G/C 67.6 24.3 8.1 51.3 36.3 12.5 0.9 (0.3–2.6) 0.84 33.3 45.8 20.8 62.5 35.4 2.1 4.2 (1.3–13.4) 0.02 0.01
TNFα 1800629 A/G 89.2 10.8 0 69.2 29.5 1.3 0.4 (0.1–1.9) 0.24 52.4 47.6 0 66.7 31.0 2.4 10.4 (1.1–102.6) 0.04 0.01
MBL2 7096206 G/C 67.5 30.0 2.5 69.1 28.4 2.5 0.9 (0.3–2.6) 0.79 79.2 20.8 0 65.9 27.3 6.8 0.2 (0.0–0.9) 0.04 0.05
F7 6046 A/G 82.4 17.6 0 80.3 18.4 1.3 0.3 (0.1–1.5) 0.15 90.9 9.1 0 64.1 30.8 5.1 0.0 (0.0–0.6) 0.03 0.02
RAGE 3134945 A/C 76.7 20.9 2.3 65.5 28.7 5.7 0.4 (0.1–1.5) 0.19 47.8 52.2 66.0 30.0 4.0 7.6 (1.1–54.1) 0.04 0.01

Abbreviations: CI, confidence interval; OR, odds ratio; RS, reference sequence.

a

Cases are infants who died by the age of 1 year or developed CP, mental, or psychomotor delay by the age of 2 years. Controls were survivors with normal neurodevelopment, defined as Bayley MDI and PDI ≥85, and no diagnosis of CP, periventricular leukomalacia or grade III/IV intraventricular hemorrhage.

b

Additive genetic model used. All models adjusted for gestational age at birth, maternal education level, and exposure to magnesium sulfate (MgSO4). Maternal race/ethnicity was controlled through matching. Results reported for polymorphisms associated with composite adverse neurodevelopmental outcome at p < 0.05 for heterogeneity across strata. No loci were significantly different between males and females after correction for multiple comparisons.